Neurocritical Care News

BOSTON — Treatment with LX9211 reduced pain related to postherpetic neuralgia and may be a valuable addition to current options for peripheral neuropathic pain, according to a presenter at the American Academy of Neurology annual meeting.

The American Academy of Neurology has elected Carlayne E. Jackson, MD, FAAN, a neurologist, researcher and professor of neurology and otolaryngology at the University of Texas Health Science Center at San Antonio, as its 38th president.

The FDA has approved Qalsody, an antisense oligonucleotide, to treat individuals with ALS associated with a mutation in the superoxide dismutase 1 gene.

The FDA has granted fast track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping, Avidity Biosciences announced in a press release.

BOSTON — For centenarians hospitalized with stroke, outcomes after treatment were affected by presenting stroke severity and ambulatory status at discharge, according to a poster at the American Academy of Neurology annual meeting.

BOSTON — An evaluation of the Utah Population Health Database showed familial clustering of stiff-person syndrome along with other autoimmune diseases, Justin Abbatemarco, MD, said at the American Academy of Neurology annual meeting.

BOSTON — Mental health symptoms in surrogate decision-makers were highest when patients survived in a dependent state after severe acute brain injury, according to a poster at the American Academy of Neurology annual meeting.

BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.

BOSTON — The SemontPlus maneuver led to quicker recovery than the Epley maneuver in patients with posterior canal benign paroxysmal positional vertigo, according to research presented at the American Academy of Neurology annual meeting.

BOSTON — Now that there are disease-modifying treatments for Alzheimer’s disease, the necessity of identifying “contemporary population-level diagnosis rates of mild cognitive impairment and dementia” is crucial, according to a presenter.